Negative phase 3 study of 90Y microspheres versus sorafenib in HCC

Negative phase 3 study of ⁹⁰Y microspheres versus sorafenib in HCC

Research output: Contribution to journal › Letter › peer-review

11 Scopus citations

@article{71413d45b2774e7a87739e7d548b57bc,

title = "Negative phase 3 study of 90Y microspheres versus sorafenib in HCC",

author = "Llovet, {Josep M.} and Finn, {Richard S.}",

year = "2018",

month = feb,

doi = "10.1016/S1470-2045(18)30025-1",

language = "English",

volume = "19",

pages = "e69",

journal = "The Lancet Oncology",

issn = "1470-2045",

publisher = "Elsevier Ltd.",

number = "2",

}

TY - JOUR

T1 - Negative phase 3 study of 90Y microspheres versus sorafenib in HCC

AU - Llovet, Josep M.

AU - Finn, Richard S.

PY - 2018/2

Y1 - 2018/2

UR - http://www.scopus.com/inward/record.url?scp=85044437445&partnerID=8YFLogxK

U2 - 10.1016/S1470-2045(18)30025-1

DO - 10.1016/S1470-2045(18)30025-1

M3 - Letter

C2 - 29413470

AN - SCOPUS:85044437445

SN - 1470-2045

VL - 19

SP - e69

JO - The Lancet Oncology

JF - The Lancet Oncology

IS - 2

ER -